New York University Langone School of Medicine, New York, NY [email protected]
In addition to previously disclosed financial relationships, Dr. Friedman reports the following financial relationships in existence at the time of publication of the review article: receiving consulting fees through his institution from Acorda Therapeutics and Alexza Pharmaceuticals and grant support through his institution from UCB. Dr. Friedman's disclosure form has been updated at NEJM.org. Since publication of their article, Dr. Friedman reports receiving consulting fees from Cyberonics, and Dr. Devinsky reports serving on the scientific advisory board for and owning stock in Pairnomix. No further potential conflict of interest relevant to this letter was reported.
This article was published on December 16, 2015, at NEJM.org.
